Pyrotinib is a novel oral, second-generation, irreversible, pan-HER tyrosine kinase inhibitor (TKI) targeting HER1, HER2, and HER4, blocking the cell cycle in G1 phase and suppressing tumor growth (16, 17). The gene discussed is ERBB2; the disease is neoplasm.